Targeting Metabolic Reprogramming to Radiosensitize Glioblastoma Stem Cells

Targeting Metabolic Reprogramming to Radiosensitize Glioblastoma Stem Cells

Cleveland Clinic

1 month
11 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Kailin Yang, MD of Cleveland Clinic discusses targeting metabolic reprogramming to radiosensitize glioblastoma stem cells.

_________

Inhibiting two critical steps in the metabolism of glioblastoma stem cells (GSCs) attenuates GSC self-renewal and reduces tumorigenesis, finds a new study presented at the 2019 annual meeting of the American Society for Radiation Oncology (ASTRO).

“Determining how to target glioma stem cells effectively has been a major challenge in treating glioblastoma [GBM],” says Kailin Yang, MD, PhD, a radiation oncology resident at Cleveland Clinic Cancer Center who presented the abstract under the supervision of Jeremy Rich, MD, MHS, of the University of California at San Diego. “Our previous studies suggested that pyrimidine synthesis is associated with clinical outcome in glioblastoma patients, and thus is a productive place to focus our energy.”

The current study demonstrates that simultaneous targeting of two vital enzymes in the pyrimidine synthetic pathway inhibits self-renewal and tumorigenesis of GSCs.

The first enzyme is rate-limiting carbamoyl-phosphate synthetase 2, aspartate transcarbamyolase, dihydroorotase (CAD). EGFR or PTEN driver mutations demonstrated distinct CAD phosphorylation patterns. The second, dihydroorotate dehydrogenase (DHODH), catalyzes the subsequent step in pyrimidine synthesis after CAD. Targeting both enzymes with clinically approved inhibitors produced sustained inhibition of the survival, self-renewal and in vivo tumor initiation of GSCs in patient-derived xenografts, when compared with single treatments.

Read the rest here: https://consultqd.clevelandclinic.org/metabolic-reprogramming-a-promising-approach-to-tackling-therapeutic-resistance-in-glioblastoma/ 

Up Next Autoplay
How does this affect clinicians today?
How does this affect clinicians today?
Category: Brain Cancer
5 Views
Cleveland Clinic 1 month
Why Does This Subset Of Patients Respond To ONC201: It Appears To Be Very Effective In This Subset Of The Disease Because Its A Vulnerability Produced By This Mutation
Why Does This Subset Of Patients Respond To ONC201: It Appears To Be Very Effective In This Subset Of The Disease Because Its A Vulnerability Produced By This Mutation
Category: Brain Cancer
152 Views
Annual-Meeting 4 months
Other Suitable Combinations For This Agent That Could Help More People: Which Combination Makes The Most Sense For A Given Patient Will Depend On What Is Happening In Their Tumor
Other Suitable Combinations For This Agent That Could Help More People: Which Combination Makes The Most Sense For A Given Patient Will Depend On What Is Happening In Their Tumor
Category: Brain Cancer
113 Views
Annual-Meeting 4 months
Latest Data For Patients Treated With ONC201 With H3 K27M-Mutant Glioma: Median Onset Of Response Was 3 Months, Median Followup Of Slightly More Than 7 Months
Latest Data For Patients Treated With ONC201 With H3 K27M-Mutant Glioma: Median Onset Of Response Was 3 Months, Median Followup Of Slightly More Than 7 Months
Category: Brain Cancer
347 Views
Annual-Meeting 4 months
Latest Data On SurVaxM Vaccine: Doubled Progression Free Period, Patients Are Surviving About 30 Months On Vaccine, Standard Of Care Median Survival Of 15 Months
Latest Data On SurVaxM Vaccine: Doubled Progression Free Period, Patients Are Surviving About 30 Months On Vaccine, Standard Of Care Median Survival Of 15 Months
Category: Brain Cancer
108 Views
Annual-Meeting 4 months
Talazoparib First Line Treatment
Talazoparib First Line Treatment
Category: Brain Cancer
126 Views
Cancer-News 11 months
IMpassion130, Solar-1 Trial Data
IMpassion130, Solar-1 Trial Data
Category: Brain Cancer
74 Views
Cancer-News 11 months
GAPVAC-101: personalized vaccines for newly-diagnosed glioblastoma
GAPVAC-101: personalized vaccines for newly-diagnosed glioblastoma
Category: Brain Cancer
169 Views
VJOncology 1 year
IDH-specific vaccine for high-grade gliomas
IDH-specific vaccine for high-grade gliomas
Category: Brain Cancer
492 Views
VJOncology 1 year